Posted on

Clinical Challenges of Engaging PWID and MSM in HIV Care

Volume 4, Issue 6.

Linking high-risk populations like PWIDs (people who inject drugs) and MSM (men who have sex with men) to effective HIV care requires overcoming complex barriers unique to these groups.

In this issue, two of the directors from Boston’s Health Care for the Homeless Program, Dr. Jennifer Brody, Director of HIV Services and ANP Marguerite Beiser, Director of HCV Services, discuss the clinical aspects of addressing these challenges.

Take our post-test to claim CME credits.

To read a companion newsletter click here.


Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

In the Clinic: ART and Metabolic Effects

Volume 4, Issue 4.

The incidence of the metabolic complications common in people with HIV infection — bone disease, weight gain, cardiovascular disease, and liver disease — is increasing as improved antiretroviral therapies create longer lifespans.

In this issue, Dr. Suman Srinivasa and nurse practitioner Kathleen Fitch from Harvard Medical School discuss how to identify and manage these metabolic complications to help improve outcomes and quality of life in patients living with HIV.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

New ART Agents: A Clinical Perspective

Volume 4, Issue 2.

Recently approved treatment options and new antiviral therapies still under investigation — through case-based discussion, Dr. Ethel Weld from the Division of Clinical Pharmacology and Infectious Diseases at the Johns Hopkins University School of Medicine explains how the promise of these new agents can impact current clinical practice.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

In The Clinic: Improving Outcomes in At-Risk Populations

Volume 3, Issue 8.

In this podcast Drs. Allison Agwu evaluates the specific barriers to testing and entering into care among transsexual individuals, migrant and immigrant populations, and adolescents.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

New Advances in ART

Volume 3, Issue 6.

In this podcast about ART, Dr. Rachel Simmons from Boston University School of Medicine discusses recent research that may improve clinicians’ ability to more effectively and more safely manage their patients with HIV infection.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

New Options for Patients with “Hard-To-Treat” Hepatitis C Infection

Volume 5, Issue 12.

In this podcast Dr. Ira Jacobson discusses New Options for Patients with “Hard-To-Treat” Hepatitis C Infection.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Podcast (eviralhepatitis): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

HIV: Management of Concomitant Conditions

Volume 3, Issue 2.

In this podcast Dr. Alysse Wurcel discusses important drug-drug interactions that may impact the treatment of ischemic heart disease in people living with HIV, medication interactions that could influence the treatment of common comorbid diseases, and potential drug-drug interactions between antiretroviral agents and common over-the-counter medications.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study

Volume 4, Issue 8, Part 3.

Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study, presented at the April 2016 EASL meeting.

Podcast (eviralhepatitis): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

Resistance Analysis for Ledipasvir/Sofosbuvir containing regimens in patients infected with chronic HCV who have advanced liver disease or are post Liver Transplant (SOLAR-1 and 2 STUDIES)

Volume 4, Issue 8, Part 2.

Raymond T. Chung, MD from Harvard Medical School interviews Dr. Michael Charlton from Intermountain Medical Center about his abstract: Resistance Analyses for Ledipasvir/Sofosbuvir-Containing Regimens in Patients Infected with Chronic HCV Who Have Advanced Liver Disease or are Post Liver Transplant(SOLAR-1 & 2 Studies), presented at the April 2016 EASL meeting.

Podcast (eviralhepatitis): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals

Volume 4, Issue 8, Part 1.

Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals presented at the April 2016 EASL meeting.

Podcast (eviralhepatitis): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS